Healthcare -
Biotechnology - NASDAQ - US
$ 19.715
0.854 %
$ 506 M
Market Cap
-5.85
P/E
1. INTRINSIC VALUE
Balance Sheet
Tourmaline Bio, Inc.
| Current Assets | 269 M |
| Cash & Short-Term Investments | 258 M |
| Receivables | 0 |
| Other Current Assets | 10.5 M |
| Non-Current Assets | 40.2 M |
| Long-Term Investments | 36.6 M |
| PP&E | 267 K |
| Other Non-Current Assets | 3.26 M |
| Current Liabilities | 8.91 M |
| Accounts Payable | 3.58 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 5.33 M |
| Non-Current Liabilities | 40 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 40 K |
EFFICIENCY
Earnings Waterfall
Tourmaline Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 89.7 M |
| Operating Income | -89.7 M |
| Other Expenses | -16.5 M |
| Net Income | -73.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tourmaline Bio, Inc.
| Net Income | -73.2 M |
| Depreciation & Amortization | 39 K |
| Capital Expenditures | -9 K |
| Stock-Based Compensation | 6.59 M |
| Change in Working Capital | -3.15 M |
| Others | -13.1 M |
| Free Cash Flow | -77.3 M |
Wall Street Analysts Price Targets
Tourmaline Bio, Inc.
Wall Street analysts predict an average 1-year price target for TRML of $47.3 , with forecasts ranging from
a
low of
$42 to a high of $50 .
TRML Lowest Price Target
Wall Street Target
42 USD
113.04%
TRML Average Price Target
Wall Street Target
47.3 USD
140.09%
TRML Highest Price Target
Wall Street Target
50 USD
153.61%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
15.1 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Tourmaline Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
98.4 K USD 1
9-12 MONTHS
7. News
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by 2035.
seekingalpha.com
- 3 weeks ago
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York. Dr. Bhatt also serves as the Chair of Tourmaline's Cardiovascular Scientific Advisory Board (for which he is compensated).
globenewswire.com
- 3 weeks ago
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the first quarter of 2025 and outlined recent business highlights. “We continue to see growing evidence and enthusiasm for the potential of addressing IL-6-driven cardiovascular inflammation through our discussions with cardiovascular disease experts, attendance at major medical conferences, and review of constantly emerging scientific literature,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline.
globenewswire.com
- 1 month ago
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M.
globenewswire.com
- 3 months ago
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:
globenewswire.com
- 3 months ago
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB).
globenewswire.com
- 5 months ago
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board – – Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease – NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m.
globenewswire.com
- 6 months ago
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist serving as Executive Director of CPC Clinical Research and Professor of Medicine and William R.
globenewswire.com
- 7 months ago
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027 – NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the third quarter of 2024 and outlined recent business highlights. “We are proud of the continued momentum building at Tourmaline, highlighted by the formation of our Cardiovascular Scientific Advisory Board last month,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline.
globenewswire.com
- 7 months ago
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences: Truist Securities BioPharma Symposium, New York Panel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses Thursday, November 7, 2024 at 2:35 pm ET Guggenheim Securities Healthcare Innovation Conference, Boston Fireside ChatTuesday, November 12, 2024 at 1:30 pm ET Live webcasts and replays, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com . For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
globenewswire.com
- 7 months ago
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
globenewswire.com
- 8 months ago
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by 2034. The company is also exploring Pacibekitug for atherosclerotic cardiovascular disease, with phase 2 TRANQUILITY study results anticipated in the first half of 2025.
seekingalpha.com
- 8 months ago
8. Profile
Summary
Tourmaline Bio, Inc. TRML
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 506 M
Dividend Yield
0.00%
Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Contact
27 West 24th Street, New York City, NY, 10010
https://www.tourmalinebio.com
IPO
Date
May 7, 2021
Employees
74
Officers
Mr. Ryan Robinson CPA
Chief Financial Officer & Treasurer
Dr. Kevin B. Johnson M.B.A., Ph.D.
Chief Regulatory Officer
Dr. Sandeep C. Kulkarni M.D.
Co-Founder, Chief Executive Officer & Director
Dr. Susan Dana Jones Ph.D.
Chief Technology Officer
Mr. Gerhard Hagn Pharm.D.
Senior Vice President and Head of Commercial & Business Development
Dr. Kristine Erickson O.D., Ph.D.
Vice President & TA Head of Ophthalmology, Medical Research
Ms. Dora Rau
Senior Vice President & Head of Quality
Mr. W. Bradford Middlekauff J.D.
Chief Business Officer, General Counsel & Corporate Secretary
Ms. Kimberly Piorkowski
Vice President of People, Culture & Compliance
Dr. Emil M. deGoma M.D.
Senior Vice President of Medical Research